Antibody Drug Conjugates (ADC) Market Size, Share, Growth Analysis, By Product (Kadcyla, Enhertu), By Linker Type (Cleavable Linkers, Non-Cleavable Linkers), By Target Type (HER2, CD22), By Payload Type (Monomethyl Auristatin E, Calicheamicin), By Disease Type, By Region - Industry Forecast 2024-2031

Drivers

Surging Prevalence of Cancer

• Cancer has become a worldwide public health issue as the cases of cancer keep on rising. This surge in prevalence has led to increased oncology research and high demand for drugs and treatments, which in turn is projected to boost sales of antibody drug conjugates as well.

Favorable Regulatory Approval Process

• The proven efficacy of antibody drug conjugates in managing and treating different types of cancer has pushed regulatory authorities to create expedited pathways for antibody drug conjugates to reduce their time-to-market. This favorable regulatory scenario is also expected to bolster antibody drug conjugates market growth in the future.

Restraints

High Costs of Manufacturing

• Manufacturing antibody drug conjugates requires specialized equipment, facilities, and a skilled workforce. All of these require substantial investments and therefore drive up the costs of manufacturing and result in an expensive product which ultimately slows down market development.

Safety Concerns

• Antibody drug conjugates are also faced with some severe safety concerns owing to their toxic effects on non-targeted tissues and cells. This off-target toxicity can cause complications in a patient’s health, and this is why these safety concerns impede antibody drug conjugates demand outlook.